Robert McGee, MD
Pulmonary Disease · Jackson, MSNPI 1457345456
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 190 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by GSK at 59.3% of the total. That places this record below the midpoint for pulmonary disease clinicians in MS, where the typical reported total is $4,861.
Across 190 payments — averaging $18.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- Zimvie Inc.$419
- Insmed, Inc.$255
- Actelion Pharmaceuticals US, Inc.$163
- Ceribell, Inc.$132
- Pfizer$100
- plus $330 from 10 others
What the payments were for
- Food & beverage$3,438100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 130 | $2,039 |
| Zimvie Inc. | 12 | $419 |
| Insmed, Inc. | 17 | $255 |
| Actelion Pharmaceuticals US, Inc. | 7 | $163 |
| Ceribell, Inc. | 1 | $132 |
| Pfizer | 5 | $100 |
| Inari Medical, Inc. | 4 | $64 |
| Novartis | 4 | $57 |
| Intuitive Surgical | 1 | $55 |
| Genentech USA, Inc. | 3 | $53 |
| AstraZeneca | 1 | $25 |
| Boehringer Ingelheim | 1 | $17 |
| United Therapeutics Corporation | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,438 in reported general payments places this provider in the 40th percentile of 101 pulmonary disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 12 | $268,773 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 252 | $193,219 |
| AdempasRiociguat | 12 | $162,687 |
| LetairisAmbrisentan | 12 | $155,767 |
| OpsumitMacitentan | 12 | $148,047 |
| Ambrisentan | 24 | $111,702 |
| EliquisApixaban | 138 | $106,283 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 134 | $95,241 |
| SymbicortBudesonide/Formoterol Fumarate | 179 | $50,567 |
| AdcircaTadalafil | 19 | $47,058 |
| Incruse ElliptaUmeclidinium Bromide | 82 | $33,486 |
| Breo ElliptaFluticasone/Vilanterol | 75 | $33,325 |
| XareltoRivaroxaban | 52 | $25,636 |
| Spiriva RespimatTiotropium Bromide | 35 | $19,138 |
| Spiriva HandihalerTiotropium Bromide | 25 | $14,500 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $163 | $416,81924 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta | $2,039 | $260,030409 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Daliresp | $25 | $151,606326 claims |
| PfizerEliquis | $100 | $106,283138 claims |
| United Therapeutics CorporationAdcirca | $16 | $47,05819 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $17 | $27,00052 claims |
| Johnson & JohnsonXarelto | $16 | $25,63652 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 101 pulmonary disease providers in Mississippi.
Other pulmonary disease in Jackson
- Demondes HaynesJackson$809K
- Michal SenitkoJackson$185K
- Andrew WilhelmJackson$51K
- Raymond PortisJackson$39K
- George AbrahamJackson$23K
- Maria RappaiJackson$20K
- Arash SamarghandiJackson$19K
- Kimberly DobbsJackson$14K
- Rajesh PatelJackson$13K
- Charles EvansJackson$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.